ArticleOncotarget2018
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group.
Open access · diamondAbstract read
In one paragraph
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- Pathology of peripheral neuroblastic tumors.Diagnostic pathology · 2026Review
- Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Peripheral neuroblastic tumors behaving badly: an update on high-risk morphologic and molecular groupings.Virchows Archiv : an international journal of pathology · 2025Review
- Prognostic factors of neuroblastoma in limited-resource settings.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2025Article
- Mitochondrial uncoupler and retinoic acid synergistically induce differentiation and inhibit proliferation in neuroblastoma.bioRxiv : the preprint server for biology · 2024Article
- MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective.Virchows Archiv : an international journal of pathology · 2023Article
- Metastasis pattern and prognosis in children with neuroblastoma.World journal of surgical oncology · 2023Article
- Clinical significance of MYC family protein expression in surgically resected high-grade neuroendocrine carcinoma of the lung.Thoracic cancer · 2023Article
- Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma.Cancer research · 2023Article
- MYCN protein stability is a better prognostic indicator in neuroblastoma.BMC pediatrics · 2022Article
- Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups.Biomolecules · 2022Review
- A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma.Cancers · 2021Review
- The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.Cancer medicine · 2020Article
- Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma.Pediatric blood & cancer · 2020Article
- Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model.Cancer medicine · 2020Article
- Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma.Journal of the National Cancer Institute · 2019Article
- Correlation BetweenJournal of global oncology · 2019Article
- Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.Journal of pediatric surgery · 2019Article
- Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma.Oncogene · 2019Article
- Subgrouping of Unfavorable Histology Neuroblastomas With Immunohistochemistry Toward Precision Prognosis and Therapy Stratification.JCO precision oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 15 institutions in 3 countries.
Risa Niemas-TeshibaDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
Ryosuke MatsunoDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
Larry L WangDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
Xao X TangDepartment of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Bill ChiuDepartment of Surgery, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Jasmine ZekiDepartment of Surgery, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Jeannine CoburnDepartment of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, MA, 01609, USA.
Kimberly OrnellDepartment of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, MA, 01609, USA.
Arlene NaranjoDepartment of Biostatistics, Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL 32607, USA.
Collin Van RynDepartment of Biostatistics, Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL 32607, USA.
Wendy B LondonDivision of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Michael D HogartyDivision of Oncology and Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Julie M Gastier-FosterInstitute of Genomic Medicine, Nationwide Children's Hospital and Departments of Pathology and Pediatrics, Ohio State University College of Medicine, Columbus, OH 43210, USA.
A Thomas LookDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Julie R ParkDepartment of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA 98105, USA.
John M MarisDivision of Oncology and Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Susan L CohnDepartment of Pediatrics, Division of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA.
Robert C SeegerDivision of Hematology/Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
Shahab AsgharzadehDivision of Hematology/Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
Naohiko IkegakiDepartment of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Hiroyuki ShimadaDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
Children's Hospital of Los Angeles · USUniversity of Illinois Chicago · USWorcester Polytechnic Institute · USBoston Children's Hospital · USCancer Research Center · USChildren's Hospital of Philadelphia · USChildren's Oncology Group · USChildren's Oncology Group · CHDana-Farber Cancer Institute · USLoyola University Chicago · USNationwide Children's Hospital · USUniversity of California, Los Angeles · USUniversity of Chicago · USUniversity of Pennsylvania · USUniversity of Southern California · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MCOG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MVascular endothelial cell integrins in angiogenesisP01CA081403 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI SEEGER, ROBERT CHARLES · 2000 to 2014
$28.5MFocal Sustained Release Chemotherapy-Loaded Biomaterials at Tumor SitesR01NS094218 · NINDS · TUFTS UNIVERSITY MEDFORD · PI CHIU, BILL, KAPLAN, DAVID L. · 2017 to 2021
$1.7MMYCN Function in NeuroblastomaR01CA127571 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI IKEGAKI, NAOHIKO · 2008 to 2012
$1.6MNCI NIH HHS P01 CA081403NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA127571NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NINDS NIH HHS R01 NS094218
Abstract
Neuroblastomas with a high mitosis-karyorrhexis index (High-MKI) are often associated with
Indexed as
aminoacyl-tRNA synthetaseCX-5461halofuginonenucleolar hypertrophyprotein translation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.